|
Sep 26
|
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
|
Sep 24
|
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
|
|
Jun 27
|
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
|
|
May 15
|
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Mar 26
|
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
|
|
Dec 6
|
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
|
|
Dec 4
|
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
|